Showing 5111-5120 of 5771 results for "".
- EyeSouth Establishes Presence in Alabama Through Affiliation with Montgomery Eye Physicianshttps://modernod.com/news/eyesouth-establishes-presence-in-alabama-through-affiliation-with-montgomery-eye-physicians/2476711/EyeSouth Partners has announced that it has completed an affiliation with Montgomery Eye Physicians and Prescription Eyewear. The affiliation will be EyeSouth’s first in Alabama. Terms of the deal were not disclosed. EyeSouth is an eye care-focused management services organization.
- Nicox Signs Agreement for NCX 4251 in China with Ocumension Therapeutics for Up to €12 Millionhttps://modernod.com/news/nicox-signs-agreement-for-ncx-4251-in-china-with-ocumension-therapeutics-for-up-to-e12-million/2476710/Nicox SA and Ocumension Therapeutics announced they have entered into an exclusive license agreement for the development and commercialization of Nicox’s product candidate, NCX 4251—currently in a phase 2 trial in the United States in patients with acute exacerbations of blepharitis—for a territo
- Novartis Completes Acquisition of Xiidrahttps://modernod.com/news/novartis-completes-acquisition-of-xiidra-bolstering-ophthalmic-portfolio/2476707/Novartis announced that it has completed its acquisition of Xiidra (lifitegrast ophthalmic solution) 5%, the first and only prescription treatment approved to treat both signs and symptoms of dry eye by inhibiting inflammation caused by the disease. In May, Novartis agreed to acquire Xiidr
- Alcon Launches New Dailies Colors Contact Lenseshttps://modernod.com/news/alcon-launches-new-dailies-colors-contact-lenses/2476702/Alcon officially announced the launch of new Dailies Colors contact lenses—daily disposable contact lenses that combine eye color enhancement with the convenience of a daily wear, according to a company news release. The new line features four colors—Mystic Blue, Mystic Gray, Mystic Hazel and Mys
- VSP Global Enters Into Definitive Agreement To Acquire Visionworkshttps://modernod.com/news/vsp-global-enters-into-definitive-agreement-to-acquire-visionworks/2476699/VSP Global announced that it has entered into a definitive agreement to acquire San Antonio, Texas-based Visionworks, which has more than 700 stores in 40 states. The Visionworks acquisition will be the single largest VSP network investment in the company’s
- BlephEx Asserts Claims of Patent Infringement and False Advertising Against Myco Industrieshttps://modernod.com/news/blephex-asserts-claims-of-patent-infringement-and-false-advertising-against-myco-industries/2476700/BlephEx, creator of the BlephEx device and eyelid cleaning procedure, announced that it has asserted claims of willful patent infringement and false advertising against Myco Industries and John R
- Alan R. Morse, JD, PhD, Vision and Healthcare Services Innovator, Will Retire As President & CEO of Lighthouse Guildhttps://modernod.com/news/alan-r-morse-jd-phd-vision-and-healthcare-services-innovator-will-retire-as-president-ceo-of-lighthouse-guild/2476695/James M. Dubin, Chairman of the Board of Lighthouse Guild, announced that Alan R. Morse, JD, PhD, will be stepping down later this year as President & CEO of Lighthouse Guild after an extraordinary career of almost 52 years as a leader and innovator in the field
- Promedica International and Dr. Agarwal’s Eye Hospitals Form Strategic Alliancehttps://modernod.com/news/promedica-international-and-dr-agarwals-eye-hospitals-form-strategic-alliance/2476696/Promedica International (PMI) and Dr. Agarwal’s Eye Hospitals (AEH) have formed a new partnership to conduct clinical trials in India, which they announced at the OCTANe Ophthalmology Technology Summit. PMI and AEH em
- Aldeyra Therapeutics Phase 3 SOLACE Trial Fails to Meet Primary Endpoint in Noninfectious Anterior Uveitishttps://modernod.com/news/aldeyra-therapeutics-phase-3-solace-trial-fails-to-meet-primary-endpoint-in-noninfectious-anterior-uveitis/2476691/Aldeyra Therapeutics announced results from the noninfectious anterior uveitis SOLACE trial. Statistical significance was not achieved for the primary or secondary endpoints, due to high rates of disease resolution in vehicle-treated patients, but activity of reproxalap was consistently greater t
- New CPT Code for Automated Point-of-Care Retinal Imaginghttps://modernod.com/news/new-cpt-code-for-automated-point-of-care-retinal-imaging/2476690/Artificial intelligence diagnostics company IDx announced that the American Medical Association (AMA) has accepted a new category 1 CPT code for automated point-of-care retinal imaging. This new code, submitted by the American Academy of Ophthalmology (AAO) with the support of IDx, facilitates co